<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="123168">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01499147</url>
  </required_header>
  <id_info>
    <org_study_id>2000-0117</org_study_id>
    <nct_id>NCT01499147</nct_id>
  </id_info>
  <brief_title>Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies</brief_title>
  <official_title>Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      New conditioning regimens are still needed to maximize efficacy and limit treatment-related
      deaths of allogeneic transplantation for advanced hematologic malignancies. Over the past
      several years, the investigators have evaluated several new conditioning regimens that
      incorporate fludarabine, a novel immunosuppressant that has limited toxicity and that has
      synergistic activity with alkylating agents. Recent data have suggested that fludarabine may
      be used in combination with standard doses of oral or IV busulfan, thus reducing the
      toxicity previously observed with cyclophosphamide/ busulfan regimens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment-related mortality and recurrence of disease account for the majority of treatment
      failures in allogeneic transplantation for advanced hematologic malignancies. The most
      commonly utilized conditioning regimens consist of cyclophosphamide and total-body
      irradiation or busulfan and cyclophosphamide. Other agents such as etoposide or thiotepa are
      sometimes added to maximize the antileukemic effect. New conditioning regimens are however
      still needed to maximize efficacy and limit treatment-related deaths. Over the past several
      years, the investigators have evaluated several new conditioning regimens that incorporate
      fludarabine, a novel immunosuppressant that has limited toxicity and that has synergistic
      activity with alkylating agents. Recent data have suggested that fludarabine may be used in
      combination with standard doses of oral or IV busulfan, thus reducing the toxicity
      previously observed with cyclophosphamide/ busulfan regimens.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2000</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the rate of engraftment.</measure>
    <time_frame>Up to 30 days post-transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the rate of moderate to severe (grade 2-4) acute and chronic graft versus host disease (GVHD).</measure>
    <time_frame>Up to 100 days post-transplant (acute GVHD).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the 100 day transplant-related mortality.</measure>
    <time_frame>Up to 100 days post-transplant.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the rate of engraftment.</measure>
    <time_frame>Up to 90 days post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the rate of moderate to severe (grade 2-4) acute and chronic graft versus host disease (GVHD).</measure>
    <time_frame>Up to two years post-transplant (chronic GVHD).</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Leukemia</condition>
  <condition>Chronic Myelogenous Leukemia</condition>
  <condition>Malignant Lymphoma</condition>
  <condition>Hodgkin's Disease</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Lymphocytic Leukemia</condition>
  <condition>Myeloproliferative Disorder</condition>
  <condition>Polycythemia Vera</condition>
  <condition>Myelofibrosis</condition>
  <condition>Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients below age 55 should receive fludarabine/busulfan and ATG in case of unrelated or mismatched donor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients above age 55 or below age 65 should receive fludarabine/ melphalan and ATG.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine/busulfan</intervention_name>
    <description>All patients below age 55, should receive fludarabine/busulfan, and ATG in case of unrelated or mismatched donor, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 &lt;40%, DLCO&lt;50%, LVEF&lt;40, Serum bilirubin &gt;1.5 mg% or serum transaminases &gt; 2x nl) and/or specific medical conditions such as preventing a standard myeloablative treatment, as per discussion with the PI.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Fludarabine:</other_name>
    <other_name>Fludarabine Phosphate</other_name>
    <other_name>Fludara</other_name>
    <other_name>Busulfan:</other_name>
    <other_name>Busulfex</other_name>
    <other_name>Myleran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine/ melphalan</intervention_name>
    <description>All patients above age 55 or below age 65, should receive fludarabine/melphalan, and ATG, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 &lt;40%, DLCO&lt;50%, LVEF&lt;40, Serum bilirubin &gt;1.5 mg% or serum transaminases &gt; 2x nl).</description>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Fludarabine:</other_name>
    <other_name>Fludarabine phosphate</other_name>
    <other_name>Fludara</other_name>
    <other_name>Melphalan:</other_name>
    <other_name>Alkeran</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with the following diseases:

               -  Acute myeloid or lymphocytic leukemia in first remission at standard or
                  high-risk for recurrence.

               -  Acute leukemia in greater than or equal to second remission, or with early
                  relapse, or partial remission.

               -  Chronic myelogenous leukemia in accelerated phase or blast-crisis.

               -  Chronic myelogenous leukemia in chronic phase

               -  Recurrent or refractory malignant lymphoma or Hodgkin's disease

               -  Multiple myeloma.

               -  Chronic lymphocytic leukemia, relapsed or with poor prognostic features.

               -  Myeloproliferative disorder (polycythemia vera, myelofibrosis) with poor
                  prognostic features.

               -  Severe aplastic anemia after failure of immunosuppressive therapy.

          -  Age 10-65 years.

          -  Zubrod performance status less than or equal to 2.

          -  Adequate cardiac and pulmonary function. Patients with decreased LVEF &lt; 40% or DLCO &lt;
             50% of predicted will be evaluated by cardiology or pulmonary prior to enrollment on
             this protocol.

          -  Patient or guardian able to sign informed consent.

        Exclusion Criteria:

          -  Life expectancy is severely limited by concomitant illness.

          -  Serum creatinine greater than 1.5 mg/dL or Creatinine Clearance less than 50 ml/min .

          -  Serum bilirubin greater than or equal to 2.0 mg/dl, SGPT greater than 3 x upper limit
             of normal

          -  Evidence of chronic active hepatitis or cirrhosis

          -  HIV-positive

          -  Patient is pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Damiano Rondelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Illinois at Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 27, 2014</lastchanged_date>
  <firstreceived_date>November 23, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Damiano Rondelli, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Acute myeloid leukemia</keyword>
  <keyword>First remission</keyword>
  <keyword>Acute lymphocytic leukemia</keyword>
  <keyword>Acute leukemia</keyword>
  <keyword>Second remission</keyword>
  <keyword>Early relapse</keyword>
  <keyword>Partial remission</keyword>
  <keyword>Chronic myelogenous leukemia</keyword>
  <keyword>Accelerated phase</keyword>
  <keyword>Blast-crisis</keyword>
  <keyword>Chronic phase</keyword>
  <keyword>Recurrent malignant lymphoma</keyword>
  <keyword>Refractory malignant lymphoma</keyword>
  <keyword>Hodgkin's disease</keyword>
  <keyword>Multiple myeloma.</keyword>
  <keyword>Chronic lymphocytic leukemia</keyword>
  <keyword>Myeloproliferative disorder</keyword>
  <keyword>Polycythemia vera</keyword>
  <keyword>Myelofibrosis</keyword>
  <keyword>Severe aplastic anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Vidarabine Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
